Detection of HSV Type-2, CMV and Adenovirus lgG Antibodies in Patients with Hematologic and Solid Organ Malignancies

Ramazan Uluhan; Akgün Yaman; Macit İlkit; Fatih KÖKSAL; Erol Akan

doi:10.58600/eurjther.1995-6-2-1521-arch

Authors

Ramazan Uluhan Çukurova Unv.Tıp Fakültesi Mikrobiyoloji ABD. Uz.Dr.
Akgün Yaman Çukurova Ünv. Tıp Fak Mikrobiyoloji ABD.Yrd.Doç.Dr.
Macit İlkit Çukurova Ünv.Tıp Fak Mikrobiyoloji ABD.Doktora Öğr.
Fatih KÖKSAL Çukurova Ünv. Tıp Fak Mikrobiyoloji ABD. Prof. Dr.
Erol Akan Çukurova Ünv. Tıp Fak Mikrobiyoloji ABD. Prof. Dr.

DOI:

https://doi.org/10.58600/eurjther.1995-6-2-1521-arch

Keywords:

Malignancy, HSV-2, CMV, Adenovirus

Abstract

The presence of Herpes Simplex Virus-type 2 (HSV type 2), Cytomegalovirus(CMV) and Adenovirus lgG antibodies was determined in sera from a total of 144 patients with hematologic and solid organ malignancies. HSV type-2 antibodies were detected using the EIA method and antibody levels were detected in 34(48.5 %) ofthe hematologic and in 56(75.6 %) ofthe solid organ malignancies with a total of90 (62.5 %). Anti-CMV IgG antibodies were detected in the same serum samples using the complement fixation test. Residual anti-CMV antibody levels were detected in 43(61.4) ofhematologic and 39 (52.7 %) ofsolid organ malignancies with a total of82 (56.9 %) serum samples.

Adenovinıs antibodies were detected using the complement fixation test. Residual antibodies were found in 51(72.8 %) of hematologic and in 33(44.5 %) of solid organ malignancies cut of a total of 84(58.3 %).

Metrics

Metrics Loading ...

References

Akan E:Genel ve özel Viroloji, Türkiye Klinikleri Yayınevi, 2.Baskı. Ankara, 1989.

Awidi AS:Infections in adults with cancer in a developing country, a three year prospective study. Eur J Cancer 27:4, 423-426, 1991.

Feld R:The Comproınised host. Eur J Cancer Clin Oncol 25: 1-7, 1989.

Pizzo PA:Evaluation of fever in the patient with cancer. Eur J Cancer Clin Oncol 25:9-16, 1989.

Pizz.o PA, Young RC:lnfections in the cancer patient. Devita VI, Helman S, Rosenberg SA:Cancer. Principles and Practice ofüncology.(2 nd ed.) 1985, p: 1964-1968.

Schimpff SC:Infections in the compromised host.ln:Mandell GS, Douglas RG, Jr Bennett JE:Principles and Practice of Infectious Diseases. New York, John Wiley and Sons, 1990, p:2258-2266.

Moossa AR, Robson MC, Schimpff SC:lnfections in patients with cancer. in:Comprehensive Textbook of Oncology. 1986, p:367-377.

Pizzo PA, Commers J, Cotton D,et al:Approacrung the Controversies in Antibacterial Management of Cancer Patients. Am J Med 76:436-437, 1984.

Jones PG, Rolston KVI, Fainstein V, et al:Aztreonam Therapy in Neutropenic Patients with Cancer. Am Med 81 :243-248, 1986.

Hersman J, Meyers JD, Thomas ED:The etfect of granulocyte transfusions on the incidence of cytomegalovirus infections after allogenic marrow transplantation. Ann hıtern Med 96: 149- 152, 1982.

Joshi JH, Schımptf SC, Tenney JH. et al:Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients. Am J Med 76:450, 1984.

Meyers JD, McGuffın RW, Neiman PE, et al:Toxicity and efficacy of human leukocyte interferon for treatment of cytomegalovirus pneumonia after marrow transplantation. J hıfectt Dis 141:555-562, 1980.

Pechere JC:Emergence of resistance in gram-negative bacilli during P-lactam therapy:a challenge for the future. Eur J Cancer Clin Oncol 25: 17-23, 1989.

K.lastersky J:hıfections in Comprimised Hosts:Cociderations on Prevention. Eur J Cancer Clin Oncol 25:53--01, 1989.

Wong KK, Hırsch MS:Herpes virus infections in patients with neopastic disease. Am J Med 76:464-478, 1984.

Zahradnik JM, Spencer MJ, Porter DD:Adenovirus infections in the immunocompromised patient. Am J Med 68:725-732, 1980.

Whitley RE, Whelchel J, Dietheim AG, et al:Infections caused by Herpes simplex virus in the immunocompromised host. J Infect Dis 150-3, 1984.